Insilico Medicine to Keynote at the A4M Las Vegas alongside Peter Diamandis and Valter Longo (IMAGE)

Wednesday, 13th of December, 2017, Baltimore, MD - Insilico Medicine, a Baltimore-based company specializing in the application of artificial intelligence for drug discovery, biomarker development and aging research, is pleased to announce the lecture of its founder and CEO, Dr. Alex Zhavoronkov, at 25th Annual World Congress, 14-16 Dec 2017, organized by American Academy of Anti-Aging Medicine (A4M).

Dr. Zhavoronkov's session will focus on the latest advances in artificial intelligence for development and tracking of anti-aging interventions. The lecture will cover the novel approach of developing evidence-based nutraceuticals via in silico prediction, in vitro and in vivo validation and post-marketing analysis using Young.AI project. Young.AI, currently in the beta-test version is an online service for tracking the biological age using the deep-learned photographic and basic blood biochemistry-based predictors.

"It is a privilege to speak alongside Peter Diamandis, Valter Longo, Michael Weiner and the others at the 25th annual A4M event. Insilico Medicine aspires to be the leader in artificial intelligence for longevity biotechnology and one of the many areas we are working on our evidenced-based nutraceuticals. Millions of people are consuming a broad range of nutraceuticals on a daily basis and do not track their progress. By introducing a range of nutraceuticals identified using AI and a pilot system to track their progress - Young.AI, we are trying to develop a novel drug discovery cycle that may substantially reduce the failure rates and the discovery and development time in the pharmaceutical industry", said Alex Zhavoronkov, PhD, the founder and CEO of Insilico Medicine, Inc.

"Issues following the development of novel molecules into medicines are undeniable, especially in the field of aging. Safe nutraceuticals offer one of a few ways to speed up the translation of anti-aging interventions into humans. With recent developments in the field of actionable biomarkers of biological age these interventions can be quickly evaluated by Young.AI platform", commented Alex Aliper, President of EMEA, Insilico Medicine, Inc.

Insilico Medicine was the first company to apply deep generative adversarial networks (GANs) to the generation of new molecular structures with specified parameters and published seminal papers in Oncotarget and Molecular Pharmaceutics. Another paper published in Molecular Pharmaceutics in 2016 and demonstrated the proof of concept of the application of deep neural networks for predicting the therapeutic class of the molecule using the transcriptional response data, received the American Chemical Society Editors' Choice Award. One of the recent papers published in November 2017 described the application of the next-generation AI and blockchain technologies to return the control over personal data back to the individual. 

"In the age of personal and healthcare data, it's highly important to track, understand and control your data. With Young.AI beta everyone can take advantage of the recent advances in deep learning technology to track the aging process at every level and evaluate the importance of different biomarkers. In order to better understand the effectiveness of the lifestyle as well as supplement and drug intake, Young.AI system incorporates various types of interventions and metadata", said Alexander Zhebrak, the director of product development and CTO of Insilico Medicine, Inc.

The 25th Annual World Congress in Las Vegas marks a quarter of a century since A4M began its original mission: to build awareness and deliver innovative, cutting-edge scientific education focused on longevity, and prolonging the human lifespan. The audience of the congress spans the globe, and its invited speakers, keynotes, and faculty panels assist attendees in implementing and integrating new therapies into practice.

###

For further information, images or interviews, please contact:

Contact: Qingsong Zhu, PhD 
zhu@pharma.ai 
Website: http://www.Insilico.com

Official Congress Website: https://www.a4m.com/world-congress-2017/home

About Insilico Medicine, Inc

Insilico Medicine, Inc. is an artificial intelligence company headquartered at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore, with R&D and management resources in Belgium, Russia, UK, Taiwan and Korea sourced through hackathons and competitions. 

The company utilizes advances in genomics, big data analysis, and deep learning for in silico drug discovery and drug repurposing for aging and age-related diseases. Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI and Aging.AI and operates Chemistry.AI intended to capture the tacit knowledge of medicinal chemists. 

Through a partnership with the BitFury Group, the company is working on a range of AI solutions for blockchain to help return the power over life data back to the individual. The company raised venture capital and partnered with Juvenescence Limited, a holding company focused on longevity biotechnology. The company aspires to become the "Bell Labs" for artificial intelligence and associated technologies for healthcare and longevity biotechnology and commercialize its research by forming subsidiaries around the specific technologies and licensing the intellectual property, molecules and data to the biotechnology and pharmaceutical companies. In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8

Insilico Medicine Named to the Global Top 100 AI Companies by CB Insights

INSILICO MEDICINE NAMED TO THE 2018 AI 100, HIGHLIGHTING ADVANCEMENTS IN DEEP LEARNING FOR DRUG DISCOVERY AND LONGEVITY BIOTECHNOLOGY

CB Insights today named Insilico Medicine to the prestigious AI 100, a select group of promising private companies working on groundbreaking artificial intelligence technology. CB Insights CEO and co-founder Anand Sanwal will reveal the full list of the second annual AI 100 companies at the A-ha! conference in San Francisco.

"Last year's AI 100 enjoyed amazing success in the year since earning this recognition. 55 of them went onto raise additional funding nearing $2B and 5 were acquired. This year's list was culled from 1000+ applications and looks even more impressive. These are companies using artificial intelligence in industries from drug discovery and cybersecurity to robotics and legal tech. I'm happy that CB Insights is able to shine a light on the founders and companies that will revolutionize these industries and look forward to seeing what they do in 2018 and beyond." said CB Insights CEO Anand Sanwal.

The CB Insights research team selected the AI 100 companies based on criteria, examining company-submitted data and the company’s Mosaic Score. The Mosaic Score, based on CB Insights’ National Science Foundation-funded algorithm, measures the overall health and growth potential of private companies. Through this evidence-based, statistically-driven approach, the Mosaic Score can help predict a company’s momentum, market health and financial viability. 

“In 2014 Insilico Medicine made a bet on the deep learning technology and since then established over 250 industry and academic collaborations in both drug discovery and biomarker development and we became an innovation driver for the pharmaceutical industry. We are very happy to be recognized as one of the top 100 global AI companies by CB Insights, one of the top industry analysts,” said Alex Zhavoronkov, PhD, the CEO of Insilico Medicine, Inc

In May 2017 Insilico Medicine was named top 5 AI companies for social impact by Nvidia. It pioneered the application of the generative adversarial networks (GANs) and reinforcement learning to generation of new molecular structures with the specific set of characteristics. It also pioneered using age as the main feature for multi-modal multi-omics data integration, biomarker development, target identification and transfer learning. 

“In 2014 we just got our signaling pathway perturbation analysis algorithms to work very well after several years of hard work and got venture capital to develop them further. We even got some freedom and the tools to focus on our primary interest - aging research. So the idea of refocusing the company into deep learning, which was very new back then was met with some internal resistance. But nowadays we probably have one of the most efficient and productive DL teams in the world. We are hiring through hackathons and competitions in the many countries, where the DL talent is not overpriced and bridge the gap between the DL scientists, biologists and medicinal chemists very quickly. We also perform literature reviews at least twice a week to ensure that we incorporate all of the latest advances in DL into our models. We are happy to see that this hard work is recognized by CB Insights.” said Alex Aliper, president of Europe, Insilico Medicine, Inc.

Insilico Medicine was the first company to apply deep generative adversarial networks (GANs) to the generation of new molecular structures with specified parameters and published seminal papers in Oncotarget and Molecular Pharmaceutics. Another paper published in Molecular Pharmaceutics in 2016 and demonstrated the proof of concept of the application of deep neural networks for predicting the therapeutic class of the molecule using the transcriptional response data, received the American Chemical Society Editors' Choice Award. One of the recent papers published in November 2017 described the application of the next-generation AI and blockchain technologies to return the control over personal data back to the individual. 

About CB Insights
Our team builds technology that helps corporations guess less and win more. We aggregate and analyze terabytes of data and use machine learning, algorithms and data visualization to help corporations replace the three Gs (Google searches, gut instinct and guys with MBAs) so they can answer massive strategic questions using probability not punditry.

Contact:
Farrah Kim, Senior Public Relations & Communications Manager
fkim(at)cbinsights.com
212-292-3148

For more information about the AI 100, visit:
https://www.cbinsights.com/research-ai-100

About Insilico Medicine, Inc
Insilico Medicine, Inc. is an artificial intelligence company located at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore, with R&D resources in Belgium, Russia, and the UK sourced through hackathons and competitions.

The company utilizes advances in genomics, big-data analysis, and deep learning for in silico drug discovery and drug repurposing for aging and age-related diseases. The company is pursuing internal drug discovery programs in cancer, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging.

Through its Pharma.AI division, Insilico provides advanced machine learning services to biotechnology, pharmaceutical, and skin care companies, foundations and national governments globally. In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. http://www.insilico.com

Contact:
Qingsong Zhu, PhD

zhu(at)pharma.ai

Study using artificial intelligence to identify compounds that mimic the longevity effects of calorie restriction published in November 2017 issue of Aging Journal

GEROPROTECT™ Longevity A.I.™ From Life Extension® provides anti-aging extracts that targets the anti-aging pathways as calorie restriction mimetics found in the study.

A study published in the November 15, 2017 issue of the Aging Journal addressed the need to identify nutraceuticals—safe, naturally-occurring compounds—that mimic the anti-aging effects of calorie restriction, and revealed how these compounds were identified using artificial intelligence. 

Calorie restriction is associated with enhanced longevity. However, for many it is an impractical or impossible long-term strategy. Thus, the goal of this study was to identify compounds that activate the same anti-aging pathways as a calorie restriction mimetic.

The study, a collaboration between Insilico Medicine and Life Extension, applied gene expression data from the Library of Integrated Network-based Cellular Signatures (LINCS) L1000 dataset to map the gene- and pathway-level signatures of a calorie restriction mimetic and screened for matches among over 800 natural compounds. They then predicted the safety of each compound with an ensemble of deep neural network classifiers. 

Several complementary approaches were employed including conventional statistical methods, pathway scoring-based methods, and training of deep neural networks (DNN) for signature recognition. To evaluate potential adverse effects of top-scoring natural compounds, a set of deep learned predictors, trained on transcriptional response data, were utilized.

This study also revealed promising candidates for future experimental validation while demonstrating the applications of powerful screening methods for this and similar endeavors. Moreover, the scientific research opportunities that this presents are as endless as the contributions that a socially and economically active, secure and healthy aging population can bring to society.

Life Extension utilized the findings of this artificial intelligence empowered study to develop a novel dietary supplement called GEROPROTECTTM Longevity A.I. Longevity A.I, is an innovative combination of three natural nutrients, withaferin a, gamma-linolenic acid, and ginsenoside Rg3 from Asian ginseng, that mimic known metabolic regulators of the same anti-aging pathways targeted by calorie restriction mimetics, which have long been associated with increased life expectancy.

"GEROPROTECT™ Longevity A.I.™ is the only formation to combine three potential life-prolonging ingredients into a single supplement," said Andrew G. Swick, Ph.D., senior vice president, product development and scientific affairs at Fort Lauderdale, Fla.-based Life Extension. "This unique formulation based on proprietary artificial intelligence technology contains these geroprotector ingredients in concentrations several magnitudes higher than conventional dietary supplements. We suggest that this novel formulation should be a keystone product in all life extensionists' supplement regimens."

Insilico, a next-generation artificial intelligence company specializing in the application of deep learning proprietary technology for biomarker development and aging research, used pioneering high-performance computer simulations to probe of the effect of extracts on anti-aging pathways.  

The company is located at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore. Insilico utilizes advances in genomics, big-data analysis, and deep learning for developing products for various health related industries. 

"We researched thousands of natural compounds and their combinations using our proprietary deep-learning artificial intelligence technology to identify the optimal combination of ingredients that activate the same anti-aging pathways as a calorie restriction mimetic," said Alex Zhavoronkov, Ph.D. and chief executive officer of Insilico Medicine, Inc. "Without this technology our search to swiftly fight back against aging would have literally taken decades to determine and achieve."

Full text of the study can be found at http://www.aging-us.com/article/101319/text#fulltext.

For over 37 years, Life Extension has been a pioneer in funding and reporting the latest anti-aging research and integrative health support while offering superior-quality dietary supplements. Life Extension develops and manufactures more than 350 science-based formulations that set the standard for quality, purity, and potency. A trailblazer in the $37 billion U.S. dietary supplements industry, Life Extension has a long history of offering prescient health guidance to American consumers, often years ahead of the mainstream medical establishment. Life Extension is an organization dedicated to finding new scientific methods to enhance and expand the healthy human life span. It funds research programs aimed at developing new scientific breakthroughs and has donated more than $175 million to anti-aging studies.

Chemistry.AI to analyze the brain activity of medicinal chemists for AI-powered drug discovery

Insilico announces a new crowd-sourced platform that will use EMOTIV's neuroscientific data collection and processing to perform the first Turing test for molecules generated using AI and to involve the medicinal chemists into AI-powered drug discovery

Wednesday, 22nd of November, 2017, Baltimore, MD, Insilico Medicine, a Baltimore-based next-generation artificial intelligence company specializing in the application of deep learning for drug discovery announced the launch of the first phase of the Chemistry.AI program. Chemistry.AI is a crowd-sourced platform for analyzing the brain's response of medicinal chemists to the molecules developed using artificial intelligence technologies and other expert medicinal chemists. The neuroscientific response is evaluated by analyzing the brain activity of the medicinal chemists using a ubiquitous mobile electroencephalography (EEG) device called EPOC+ produced by EMOTIV. EPOC+ also provides data about head motion and certain facial expressions. EMOTIV, the world leader in consumer EEG offers brain sensors and cloud-computing solutions to scale the collection and processing of behavioral and brain data that will be used together with eye-tracking and video monitoring techniques in the current project.

"Using our mobile sensors and cloud computing solutions to better understand the brain activity of medicinal chemists, will provide unique insights on what distinguishes experts chemists from others, that no other methodology could", said Tan Le, CEO of EMOTIV (@tanttle)

"Medicinal chemists with several years of experience have the ability to distinguish the good molecules from the bad ones just by looking at their structure or its numerical properties and various scores. Depending on their prior experience with the various types of chemistry, e.g. kinase chemistry or GPCR chemistry and their background, their assessment is often biased. With Chemistry.AI we are hoping to achieve two major goals: capture the tacit knowledge possessed by medicinal chemists and put the output of the molecules generated using AI to the test by some of the best human scientists in a version of a Turing test", said Alex Zhavoronkov, PhD, the founder of Insilico Medicine, Inc. 

Medicinal chemistry is among one of the most important and intellectually-challenging professions on the planet. It takes decades of training and experience to learn the properties of the thousands of molecules and their effects on the biological systems, model organisms and diseases. Decisions made by the medicinal chemists affect the lives of billions of people and may result in the billions of dollars of gains or losses for the pharmaceutical companies.

Experienced medicinal chemists have the ability to accurately describe the properties and the possible effects of the molecule just by looking at its structure, as well as at the various numerical parameters.

They may favour certain molecular structures because of their experience with the hundreds of thousands of molecules they encountered previously and the emotional response to the molecule is usually biased and related to the molecules and the classes of molecules they are most familiar with.

Chemistry.AI will provide a platform for the medicinal chemists to look at the various classes of molecules and measure their brain activity and other physiological parameters during the exposure to the molecule.

###

For further information, images or interviews, please contact:

Contact: Qingsong Zhu, PhD 
zhu@pharma.ai

Website: http://www.Insilico.com

About Insilico Medicine, Inc

Insilico Medicine, Inc. is an artificial intelligence company located at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore, with R&D resources in Belgium, Taiwan, Russia, and the UK sourced through hackathons and competitions.

The company utilizes advances in genomics, big-data analysis, and deep learning for in silico drug discovery and drug repurposing for aging and age-related diseases. The company is pursuing internal drug discovery programs in cancer, dermatological diseases, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging itself.

Through its Pharma.AI division, Insilico provides advanced machine learning services to biotechnology, pharmaceutical, and skin care companies, foundations and national governments globally. In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. http://www.insilico.com

About EMOTIV

EMOTIV is the leading mobile bioinformatics company, advancing understanding of the human brain using electroencephalography (EEG). Its mission is to empower individuals to understand their own brain and accelerate brain research globally. 

EMOTIV has developed unique machine learning algorithms that allow the user to track cognitive performance, detect facial expressions and control both virtual and physical objects via trained mental commands.

EMOTIV leads the field of mobile brain sensors in terms of innovation, technology and support from the scientific community. Its technology is currently being used in more than 110 countries by more than 80,000 individuals who own one of its brainwear. It has been validated and included in over 4,000 publications. EMOTIV believes in the power of the human brain and the ability to tap into its potential to open up new possibilities for improving performance, health, wellness and ultimately, prevent disease. https://www.emotiv.com/

Converging blockchain and next-generation AI technologies to accelerate biomedical research

Blockchain and AI researchers propose a new model to return the control over human life data to the patients and accelerate biomedical research

Wednesday, 15th of November, 2017, 10AM EST, Baltimore, MD, Insilico Medicine, a Baltimore-based next-generation artificial intelligence company specializing in the application of deep learning for drug discovery announced the publication of a new peer-reviewed research paper titled" Converging blockchain and next-generation artificial intelligence technologies to decentralize and accelerate biomedical research and healthcare" in Oncotarget. Insilico Medicine scientists specializing in deep learning collaborated with the scientists and developers from the Bitfury Group, the world's leading full service Blockchain technology company, specializes in securing the Blockchain and deploying cutting edge hardware and software solutions to governments, institutions, and corporations. In the paper the groups presented the first attempt to assess the value of time and the combination value of personal data in the context of an AI-mediated health data exchange on blockchain. 

"Most people do not understand what life data they have, how valuable and dangerous this data may be and do not have any control over how their life data is being used. The policy makers are trying to address this problem by introducing new regulations that make it expensive and difficult for the innovators to turn the human life data into life-saving products. In this paper we propose a blockchain-enabled solution to help people become aware of and take control over their data and profit from licensing the data to the innovators", said Polina Mamoshina, Sr. research scientist at Insilico Medicine. 

In this research paper scientists introduce new concepts to appraise and evaluate human life data, including the combination-, time- and relationship-value of the data and present a roadmap for a blockchain-enabled decentralized personal health data ecosystem to enable novel approaches for drug discovery, biomarker development, and preventative healthcare. A secure and transparent distributed personal data marketplace utilizing blockchain and deep learning technologies may be able to resolve the challenges faced by the regulators and return the control over personal data including medical records back to the individuals.

"We are enthusiastic that blockchain technology can help solve one of the major problems in modern healthcare - patient data management. We are even more excited that Insilico is building this solution on our open-source Blockchain framework, Exonum. An Exonum-based Blockchain provides security, transparency and reliability, which will significantly improve overall efficiency and patient satisfaction as well as provide an avenue for easier auditing. We look forward to sharing our progress", said George Givishvili, Chief Marketing Officer of Bitfury company.

Blockchain technology enables the creation of a distributed and secure ledger of personal data, where patients are in control, own their data, and monitoring of access privileges and understanding of who looked at the data. Most importantly, blockchain technology allows for the creation of a data-driven marketplace, where patients can earn tangible rewards for making their data available to the application development community, pharmaceutical and consumer companies, and research institutions and generating new data through regular and comprehensive tests and checkups. Presently, only a few patients worldwide have the comprehensive data sets containing their clinical history combined with the genetic, blood biochemistry and cell count profiles, lifestyle data, drug and supplement use and other data types, because they do not see the value in this data and do not get tested regularly. On the other hand, the pharmaceutical and consumer companies alike are willing to pay substantial amounts for the large numbers of personal data records required to train their AI. These funds can be used to subsidize the regular testing by the patients, uncover the new uses for the various data types and develop sophisticated diagnostic and treatment tools.

"In the post neoclassical world, healthy productive longevity will be the new driver of economic growth. Creating an economy around human life data and returning the ownership and the control over life data back to the individual is one of the most important steps towards extending healthy productive longevity of the global population. It is also a very altruistic cause, which may help reduce the gap between the rich and the poor and allow the people from all walks of life and geographies to equally profit from their own data", said Alex Zhavoronkov, the founder of Insilico Medicine, Inc. 

###

For further information, images or interviews, please contact:

Contact: Qingsong Zhu, PhD

zhu@pharma.ai

Website: http://www.Insilico.com

About Insilico Medicine, Inc

Insilico Medicine, Inc. is an artificial intelligence company located at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore, with R&D resources in Belgium, Russia, and the UK sourced through hackathons and competitions.

The company utilizes advances in genomics, big-data analysis, and deep learning for in silico drug discovery and drug repurposing for aging and age-related diseases. The company is pursuing internal drug discovery programs in cancer, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging.

Through its Pharma.AI division, Insilico provides advanced machine learning services to biotechnology, pharmaceutical, and skin care companies, foundations and national governments globally. In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. http://www.insilico.com

Artificial Intelligence uncovers anti-aging plant extracts

Insilico to present on the practical applications of the pharmaceutical AI for metabesity

Tuesday, 10.24.2017, Baltimore, MD, Insilico Medicine, a leader in the field of artificial intelligence, is pleased to announce its founder and CEO, Dr. Alex Zhavoronkov, will present at The World Congress on Targeting Metabesity in London, UK on Tuesday, October 31 in Session VIII: Are New Business Models Needed? 

Dr. Zhavoronkov's presentation will focus on recent advances in artificial intelligence specifically in deep learning allow for novel ways to identify the disease targets, generate novel molecular structures for these targets, track the effects of the various interventions and improve behavior.

Metabesity refers to the major public health challenges--cardiovascular disease, cancer, dementia, diabetes and the aging process itself--all of which share metabolic roots. These metabolically connected disorders can be targeted to prevent--not just manage them. Metabesity2017 aims at these stretch goals by engaging world-renowned scientific experts, executives, policy makers, and other stakeholders across the fields of metabolic-rooted disorders. The distinctive objective of Metabesity2017 is to devise cross-cutting strategies to leverage impact of this science and technology. 

Dr. Zhavoronkov, PhD, founder and CEO of Insilico Medicine, Inc said, "Targeting metabesity is the low-hanging fruit for extending human longevity and improving the quality of life. Recent advances in artificial intelligence specifically in deep learning allow for novel ways to identify the disease targets, generate novel molecular structures for these targets, track the effects of the various interventions and improve behavior. We are very happy to present our work at this unique and most important conference, Metabesity2017, which will catalyze interdisciplinary progress."

Dr. Alexander Fleming, Founder and Chairman of Kinexum, commented: "We are delighted to have Alex participate in this inaugural congress, which annually will help to accelerate collaboration, creativity, and productivity in the fields of chronic disease prevention and healthy lifespan extension. He has not only contributed immensely to scientific and technical progress, but he is the personal embodiment of what the Metabesity movement aims to be--connecting and invigorating disparate experts, institutions, and resources to pursue daunting goals. 

###

For further information, images or interviews, please contact:

Contact: Qingsong Zhu, PhD
zhu@pharma.ai

Website: http://www.Insilico.com

About Insilico Medicine, Inc

Insilico Medicine, Inc. is an artificial intelligence company located at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore, with R&D resources in Belgium, Russia, and the UK sourced through hackathons and competitions.

The company utilizes advances in genomics, big-data analysis, and deep learning for in silico drug discovery and drug repurposing for aging and age-related diseases. The company is pursuing internal drug discovery programs in cancer, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. 

Through its Pharma.AI division, Insilico provides advanced machine learning services to biotechnology, pharmaceutical, and skin care companies, foundations and national governments globally. In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. http://www.insilico.com

About Kinexum

Kinexum catalyze academic and commercial efforts to develop health products aimed at treatment and prevention of major chronic diseases as well as orphan conditions. Kinexum experts provide guidance across the spectrum of pharmaceuticals, biologics, cell therapies, nutritionals, medical devices, and digital health. Kinexum contributes, pro bono, substantially to advancing regulatory science and policy, generating guidelines and scientific publications, leading professional organizations, and bringing a diversity of experts and decision makers together.  http://www.kinexum.com

Advances in AI for drug discovery to be presented at the AI Pharma Innovation Summit 2017 in Boston

Wednesday, June 21, 2017, Baltimore, MD - Insilico Medicine, a Baltimore-based artificial intelligence company focused on drug discovery, biomarker development and aging research will present new research on applying deep learning approaches to drug discovery at the inaugural AI Pharma Innovation Summit in Boston, July 25-27. The CEO of Insilico Medicine, Alex Zhavoronkov, PhD will present new research and moderate the workshop titled "A Fundamental Guide to the Application of AI in Drug Discovery to Uncover the Next Wave of Successful Future Candidates" 15:00-17.30 on July 25th. The conference website is http://www.ai-pharma.com and early bird registration deadline is June 23rd.

"Artificial intelligence holds enormous potential for pharmaceutical R&D. In fact, mastering AI will become a key competitive advantage for pharmaceutical companies, possibly a key survival factor versus more innovative and faster moving new entrants into the biomedical space. However, the hype surrounding AI, unprecedented investments by venture capitalists and lack of industry experts and analysts are creating a bubble reminiscent of the Dot Com era. Many companies are rebranding basic computational approaches as AI to get funding and contracts. Understanding the underlying principles and various flavours of AI and what the various elements of the AI toolbox can do for the various steps of the early R&D, clinical trials and marketing process is essential for every CEO and board member of every major pharmaceutical company", said Ulrich Muehlner, PhD, former director and head of corporate strategy of Novartis, CEO of GrowthCube Partners and advisor to Insilico Medicine.

The conference will bring together some of the most prominent thought leaders in artificial intelligence for the pharmaceutical industry, pharmaceutical industry executives, regulators and academics. It will feature speakers from Pfizer, Sanofi and Novartis with the Global CIO of Novartis, Remy Evard and VP and Global Head of Digital Business, Jeremy Sohn leading a session called "Discover: Accelerating the Integration of AI in into Pharmaceutical DNA". 

"Artificial Intelligence is transforming many industries including transportation, finance and security. This will undoubtedly impact the pharmaceutical industry which will experience dramatic change over the next five years. AI will impact every process from early screening and preclinical validation to clinical trials execution, marketing, sales and general management. To adapt to this rapid pace of innovation pharma needs to adapt to the new world order and embrace AI as the source of competitive advantage and shareholder value creation", said Declan Doogan, MD, DSc, former senior vice-president and head of worldwide development at Pfizer and Chairman and co-founder of Biohaven Pharmaceuticals."

In order to facilitate this fundamental shift in the biopharma R&D model, Insilico Medicine will launch in July an executive training program codenamed "the Pharmaceutical Artificial Intelligence Strategy Executive Coach". The program is geared towards the senior company executives and board members of large biopharmaceutical corporations and international government regulatory bodies in partnership with the several prominent hardware vendors and consulting companies. 

"Artificial intelligence holds enormous potential for pharmaceutical R&D. In fact, mastering AI will The interactive workshop at the AI Pharma Innovation Summit will delve deeper into the multiple applications of AI algorithms in drug design and discovery: with major investments at stake later down the R&D pipeline, it is essential that only the best candidates are identified to progress through the pre-clinical and clinical landscapes. Immerse yourself in discussions on the following topics: 

• Supporting discovery using AI
• Training neural networks to predict molecular structures
• Improving the scaling of drug discovery efforts by utilizing AI technology
• Discussing the application of AI for target and compound selection
• Predictive analytics for drug discovery target validation
• Discussing sophisticated predictive machine learning methods to improve the speed and efficiency of drug discovery process
• Developing computational AI methods for screening
• Harnessing AI platforms to correlate label drug use and medical events to identify suitable molecules for drug repurposing

###

About Insilico Medicine, Inc

Insilico Medicine, Inc. is an artificial intelligence company located at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore with R&D resources in Belgium, Russia, and the UK hiring talent through hackathons and competitions. It utilizes advances in genomics, big data analysis and deep learning for in silico drug discovery and drug repurposing for aging and age-related diseases. The company pursues internal drug discovery programs in cancer, Parkinson's, Alzheimer's, ALS, diabetes, sarcopenia and geroprotector discovery. Through its Pharma.AI division, the company provides advanced machine learning services to biotechnology, pharmaceutical, and skin care companies. In 2017 NVIDIA selected Insilico as the top 5 AI companies for social impact. 

Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8

Artificial intelligence and blockchain companies partner to advance healthcare research

The Bitfury Group and Insilico Medicine partner to develop AI healthcare Blockchain solutions

Tuesday, 15th of August, 2017, Baltimore, MD - Insilico Medicine, Inc, a Baltimore-based next-generation artificial intelligence company today announced a research collaboration with The Bitfury Group, the world's leading full-service blockchain technology conglomerate, to develop novel solutions for healthcare applications. The companies signed a memorandum of understanding (MOU) to collaborate in the academic and commercial settings to develop AI on Blockchain solutions for the healthcare industry.

"Blockchain can secure and streamline our medical systems, while AI has the potential to revitalize data management and machine learning to help identify trends and diseases," said Valery Vavilov, founder and CEO of The Bitfury Group. "By partnering with Insilico, we will be able to combine their expertise in deep learning and bioinformatics with our Blockchain proficiency and real-time solutions to create bespoke and innovative new products for the healthcare sector."

"The Bitfury Group is one of the most reputable companies in Blockchain developing their own semiconductors and end-to-end Blockchain solutions trusted by the major corporations and governments worldwide. We are happy to enter into a research collaboration with Bitfury to develop innovative solutions that may save lives and extend human healthspan", said Alex Zhavoroknov, PhD, founder and CEO of Insilico Medicine, Inc. 

Blockchain and Artificial Intelligence

Recent advances in AI have surpassed human accuracy in image and voice recognition and are transforming multiple industries, including manufacturing, transportation, finance and entertainment. However, the use of AI in the healthcare industry has been comparatively slower than in other sectors, as deep learning systems need a large number of examples to learn from and can require up to tens of millions of data sets to achieve a high level of accuracy. 

Next-generation AI developed by Insilico Medicine can be used to validate, assess and improve the quality of biological samples as well as learn using large volumes of heterogeneous data without human intervention. Multiple new methodologies including the feature importance, deep feature selection and deep pathway analysis among the others can provide the biologically-relevant interpretation of the inner workings of the AI systems. 

Blockchain has the potential to track and validate large amounts of healthcare data in a secure and efficient ways opening the door to the necessary solutions to effectively organize data for deep learning systems. The Bitfury and Insilico Medicine partnership will explore the ways Blockchain can be used to accelerate progress in biomedicine and deliver innovative healthcare solutions to people around the world. 

Insilico Medicine is developing "next-generation AI" with the focus on deep generative adversarial networks (GANs), Reinforcement Learning (RL) and Meta Learning for drug discovery, biomarker development, cross-species analysis and aging research. It recently published on the applications of GANs to discovery of novel molecules in Oncotarget and Molecular Pharmaceutics. Another paper published in Molecular Pharmaceutics in 2016, demonstrated the proof of concept of the application of deep neural networks for predicting the therapeutic class of the molecule using the transcriptional response data, received the American Chemical Society Editors' Choice Award. 

###

About The Bitfury Group

The Bitfury Group is the leading full service Blockchain technology company and one of the largest private infrastructure providers in the Blockchain ecosystem. The Bitfury Group develops and delivers both the software and the hardware solutions necessary for businesses, governments, organizations and individuals to securely move an asset across the Blockchain. The expertise of The Bitfury Group ensures successful, easy, fast, secure and cost effective connectivity to the Blockchain. The Bitfury Group is a global team of experts in technology, business, communications, security and civil society. The Bitfury Group believes the Blockchain can and will open new doors for global economic opportunity and prosperity, and its mission is to create and advance Blockchain applications that will further promote innovation and the advancement of the peer-to peer economy. Visit bitfury.com for more information

About Insilico Medicine, Inc

Insilico Medicine, Inc. is the next-generation artificial intelligence company located at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore with R&D resources in Belgium, Russia, and the UK, hiring talent through hackathons and competitions. It develops novel AI solutions for drug discovery, biomarker development and aging research. The company pursues internal drug discovery programs in cancer, Parkinson's, Alzheimer's, ALS, metabolic diseases, sarcopenia and senescence. Through its Pharma.AI division, the company provides advanced machine learning services to biotechnology, pharmaceutical, and skin care companies. In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8

For more information please contact:

Rachel Pipan
Rachel.Pipan@bitfury.com

Qingsong Zhu, PhD 
zhu@insilicomedicine.com

Artificial intelligence for human age-reversal

Center for Healthy Aging at the University of Copenhagen today announced a research collaboration with a company specializing in artificial intelligence (AI) to develop solutions for preventing early aging. The aim of this partnership is to develop medicines to prevent and cure a broad range of diseases associated with aging such as Alzheimer's, Parkinson's and cardiovascular diseases.

Alzheimer's, Parkinson's and cardiovascular diseases are strongly associated with aging and share many characteristics on the molecular level. Experts in the genetics of aging at the Department of Cellular and Molecular Medicine partnered with the Baltimore-based company, Insilico Medicine, specializing in AI to find molecules that can be developed into drugs to cure and prevent these diseases. The objective of this collaboration is to increase health span for everyone on the planet. "Many of the diseases of aging are associated with the failure of the DNA repair mechanisms. The aging processes accelerate as the DNA repair mechanisms lose function. The collaboration with Insilico Medicine will allow us to find the molecules that repair DNA and prevent accelerated aging", said the head of the biology of aging lab and assistant professor Morten Scheibye-Knudsen, Center for Healthy Aging. 

Extended Lifespan for All

Insilico Medicine develops the advanced AI algorithms to study the aging processes and discover new interventions in aging. Many of these molecules aim to induce the expression of certain genes involved in the endogenous repair processes to slow down and even reverse some of the aging-associated diseases. By applying a specific branch of artificial intelligence called Deep Learning (DL) on multi-modal data, the company aims to discover molecules that can stimulate the repair of the DNA. 

"Deep learning systems are outperforming human abilities in many tasks including image recognition and autonomous driving. But one area, where AI will have the most impact is drug discovery and we are deeply honored to be able to partner with professor Scheibye-Knudsen's group at the University of Copenhagen, which is one of the most advanced in the world. I hope that together we will be able to find new molecules to extend healthy longevity and make humans more resistant to the various stress factors", said Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine, Inc.

At the advanced laboratories in Copenhagen, the research teams will be able to test the molecules identified using the artificial intelligence methods to select the most effective ones for joint development into novel medicines. 

"We hope that cooperation can lead to the development of some new drugs that can prevent early aging, thus ensuring increased health spans for everyone. If we can find molecules that repair our DNA, it is not inconceivable that we can increase the upper limit to how old we may be, "says Morten Scheibye-Knudsen.

Insilico Medicine was the first company to apply deep generative adversarial networks (GANs) to generation of new molecular structures with specified parameters and published a seminal papers in Oncotarget and Molecular Pharmaceutics. Another paper published in Molecular Pharmaceutics in 2016, demonstrated the proof of concept of the application of deep neural networks for predicting the therapeutic class of the molecule using the transcriptional response data, received the American Chemical Society Editors' Choice Award.

The pharmaceutical industry is expected to benefit from the recent advances in AI. Insilico Medicine was profiled in the recent article in Nature Biotechnologytitled "AI-powered drug discovery captures pharma interest" among the other companies utilizing machine learning for drug discovery. The agreement with Juvenescence is expected to set a precedent for the new molecules discovered using the new generation of artificial intelligence by a team of expert drug developers.

###

About Insilico Medicine, Inc

Insilico Medicine, Inc. is an artificial intelligence company located at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore, with R&D resources in Belgium, Russia, and the UK sourced through hackathons and competitions. The company utilises advances in genomics, big data analysis, and deep learning for in silico drug discovery and drug repurposing for ageing and age-related diseases. The company is pursuing internal drug discovery programs in cancer, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and ageing. Through its Pharma.AI division, Insilico provides advanced machine learning services to biotechnology, pharmaceutical, and skin care companies, foundations and national governments globally. In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact.

Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8

About the Scheibye-Knudsen Laboratory

The growing proportion of the elderly population represents an increasing socioeconomic challenge, not least because of age-associated diseases. It is therefore increasingly pertinent to find interventions for age-associated diseases such as Alzheimer's, Parkinson's and cardiovascular diseases. Although the cause of aging is currently unknown accumulation of damage to our genome, the DNA, may be a contributing factor.

In the Scheibye-Knudsen lab we try to understand the cellular and organismal consequences of DNA damage with the aim of developing interventions. We have discovered that DNA damage leads to changes in certain metabolites and that replenishment of these molecules may alter the rate of aging in model organisms. These findings suggest that normal aging and age-associated diseases may be malleable to similar interventions. The hope is to develop interventions that will allow everyone to live healthier, happier and more productive lives.

Laboratory website: http://scheibye-knudsen.com/

About the University of Copenhagen 

With over 40,000 students and more than 9,000 employees, the University of Copenhagen is the largest institution of research and education in Denmark and among the highest ranked universities in Europe. The purpose of the University - to quote the University Statute - is to 'conduct research and provide further education to the highest academic level'. Approximately one hundred different institutes, departments, laboratories, centres, museums, etc., form the nucleus of the University.

University website: http://introduction.ku.dk/presentation/

Contact: 
Insilico Medicine 
Dr. Qingsong Zhu 
zhu@insilicomedicine.com

University of Copenhagen 
Dr. Morten Scheibye-Knudsen 
mscheibye@sund.ku.dk